A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
详细信息 查看全文
- 作者：Michael B. Jameson ; Danny Rischin ; Mark Pegram ; John Gutheil ; Adam V. Patterson ; William A. Denny and William R. Wilson
- 关键词：PR ; 104 ; Hypoxia ; Prodrug ; Dinitrobenzamide nitrogen mustard ; Phase I
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2010
- 出版时间：March, 2010
- 年：2010
- 卷：65
- 期：4
- 页码：791-801
- 全文大小：303.5 KB
文摘
Purpose PR-104 is a “pre-prodrug” designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in hypoxic regions of tumors. This study was conducted to establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and pharmacokinetics (PK) of PR-104 in patients with advanced solid tumors.